A phase I/II study of transarterial chemoembolization with cisplatin for hepatocellular carcinoma (JIVROSG-0401)
Not Applicable
- Conditions
- nresectable hypervascular hepatocellular carcinoma
- Registration Number
- JPRN-C000000049
- Lead Sponsor
- Japan Interventional Radiology in Oncology Study Group (JIVROSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Prior chemotherapy with cisplatin for HCC. 2) Suspicious of extra-hepatic arterial blood supply to lesions on contrast-enhanced CT. 3) Extra-hepatic arterial blood supply to lesions on prior angiography. 4) Surgical reconstruction or endoscopic treatment involving biliary system. 5) Lymphnode metastasis or distant metastasis. 6) Other uncontrolled severe illness. 7) Active infectious disease except viral hepatitis. 8) Active other malignancies. 9) Allergic reaction to iodine contrast material, platinum containing agent, or gelatin containing agent. 10) Pregnant or nursing.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events
- Secondary Outcome Measures
Name Time Method Response rate of liver tumor and overall response rate